Compare Dell Technologies Inc (DELL) vs TG Therapeutics Inc (TGTX) Price & Performance

Dell Technologies (DELL) trades at $586.28, up 1.26% today, with a bullish technical outlook as the price hovers near resistance at $585. Recent earnings beats, including Q2 2026 EPS of $7.04 versus $4.91 expected, and a raised AI server revenue forecast to $74 billion for fiscal 2027 highlight strong operational momentum. The stock's valuation reflects growth expectations with a P/E of 33.42 and P/S of 2.52.

The outlook remains positive driven by AI server demand, but risks include high valuation sensitivity and competitive pressures. Analyst consensus is bullish with a $566.35 price target, though the current price exceeds this, suggesting near-term consolidation may precede further gains if execution continues.

TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.

The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.